Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Aziyo Biologics ( (ELUT) ) has provided an update.
On February 3, 2025, Elutia Inc. announced a registered direct offering, selling 5,520,000 shares of Class A common stock and 480,000 prefunded warrants, aimed at raising approximately $15.0 million before expenses. The offering, which closed on February 4, 2025, is intended to provide working capital and support general corporate purposes, reflecting Elutia’s strategic financial planning. The company agreed to a lock-up period with its directors and officers, restricting the sale or transfer of securities for 90 days post-closing, and agreed with the Placement Agent to limit issuance of new shares during this period, indicating a focus on stabilizing its share price and market position.
More about Aziyo Biologics
YTD Price Performance: -18.82%
Average Trading Volume: 39,578
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $95.39M
See more insights into ELUT stock on TipRanks’ Stock Analysis page.
